CN115671132B - Composition of probiotics and prebiotics and application thereof - Google Patents
Composition of probiotics and prebiotics and application thereof Download PDFInfo
- Publication number
- CN115671132B CN115671132B CN202211459787.9A CN202211459787A CN115671132B CN 115671132 B CN115671132 B CN 115671132B CN 202211459787 A CN202211459787 A CN 202211459787A CN 115671132 B CN115671132 B CN 115671132B
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- probiotics
- prebiotics
- orlistat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 239000006041 probiotic Substances 0.000 title claims abstract description 51
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 51
- 235000013406 prebiotics Nutrition 0.000 title claims abstract description 50
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 claims abstract description 60
- 229960001243 orlistat Drugs 0.000 claims abstract description 55
- 241000186016 Bifidobacterium bifidum Species 0.000 claims abstract description 22
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims abstract description 22
- 229920001202 Inulin Polymers 0.000 claims abstract description 19
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 19
- 229940029339 inulin Drugs 0.000 claims abstract description 19
- 229920002261 Corn starch Polymers 0.000 claims abstract description 18
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 18
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 18
- 241000186605 Lactobacillus paracasei Species 0.000 claims abstract description 18
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 18
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 18
- 239000008120 corn starch Substances 0.000 claims abstract description 18
- 235000003599 food sweetener Nutrition 0.000 claims abstract description 18
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 18
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 18
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 18
- 239000003765 sweetening agent Substances 0.000 claims abstract description 18
- 229920001353 Dextrin Polymers 0.000 claims abstract description 17
- 239000004375 Dextrin Substances 0.000 claims abstract description 17
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 17
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 17
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims abstract description 17
- 235000019425 dextrin Nutrition 0.000 claims abstract description 17
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims abstract description 17
- 230000002708 enhancing effect Effects 0.000 claims abstract description 6
- 238000002156 mixing Methods 0.000 claims description 28
- 238000002360 preparation method Methods 0.000 claims description 20
- 238000005303 weighing Methods 0.000 claims description 15
- 230000001954 sterilising effect Effects 0.000 claims description 14
- 235000013305 food Nutrition 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 230000004580 weight loss Effects 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 18
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 5
- 230000001105 regulatory effect Effects 0.000 abstract description 5
- 206010067484 Adverse reaction Diseases 0.000 abstract description 4
- 230000006838 adverse reaction Effects 0.000 abstract description 4
- 210000003608 fece Anatomy 0.000 abstract description 4
- 229940099112 cornstarch Drugs 0.000 abstract description 2
- 230000002496 gastric effect Effects 0.000 abstract description 2
- 230000036541 health Effects 0.000 abstract description 2
- 230000000968 intestinal effect Effects 0.000 abstract description 2
- 235000013376 functional food Nutrition 0.000 abstract 1
- 238000003756 stirring Methods 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 12
- 239000003921 oil Substances 0.000 description 10
- 239000003925 fat Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 239000000463 material Substances 0.000 description 6
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 5
- 229920002581 Glucomannan Polymers 0.000 description 5
- 229940046240 glucomannan Drugs 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 229940086609 Lipase inhibitor Drugs 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000009924 canning Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000013585 weight reducing agent Substances 0.000 description 2
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229940009289 bifidobacterium lactis Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009461 vacuum packaging Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention belongs to the field of functional foods, and particularly relates to a composition of probiotics and prebiotics and application thereof. A composition of probiotics and prebiotics comprises resistant dextrin, inulin, corn starch, maltodextrin, stachyose, lactobacillus plantarum, lactobacillus acidophilus, bifidobacterium bifidum, lactobacillus paracasei and sweetener. Compared with similar products in the market, the composition of the probiotics and the prebiotics has the advantages of optimizing the proportion, reducing unpleasant gastrointestinal side effects generated by the administration of orlistat, relieving adverse reactions such as oil spots, fat/oil feces and the like, synergism and enhancing the weight-losing effect. Meanwhile, the invention also has the functions of regulating the balance of intestinal flora and improving the health of intestinal tracts.
Description
The application is a divisional application with the application date of 2021.05.31, the application number of 202110599523.2 and the invention name of 'a composition of probiotics and prebiotics and application thereof'.
Technical Field
The invention belongs to the technical field of microbial preparations, and relates to a composition of probiotics and prebiotics and application thereof.
Background field
Orlistat is a lipase inhibitor, and can inhibit fat absorption of human body to obtain the goal of reducing weight, and is the only non-central nerve weight-reducing medicine, but when orlistat is taken, unpleasant gastrointestinal side effects such as anal oil leakage (oil spot), fat/oil feces, diarrhea and other adverse reactions can be produced.
A prebiotic is a non-digestible ingredient in a food or feed that is capable of selectively stimulating the growth of beneficial bacteria in the digestive tract of a host animal, thereby producing a beneficial effect on the animal. The supplementing prebiotics can promote the growth and proliferation of self probiotics in the intestinal tract, and then are matched with the ingested exogenous probiotics to promote the proliferation of the probiotics in the intestinal tract, so that the balance of intestinal flora can be better regulated, and the intestinal tract health is easy. It is studied that some prebiotics also have good adsorption on grease. Thus, the research area of extended prebiotic compositions may better serve humans.
Chinese patent CN110024932a discloses a formulation of solid beverage extracted from black fungus for reducing weight, improving diarrhea and regulating flora and its preparation method, the formulation comprises prebiotics-fructo-oligosaccharide, inulin, probiotics-lactobacillus plantarum and/or lactobacillus acidophilus and/or bifidobacterium lactis. The product described in this patent is used in the preparation of foods or special foods or medicines for reducing weight or improving diarrhea or regulating flora. However, this patent does not describe the effect of improving adverse reactions such as anal leakage (oil spot), fat/oil feces, diarrhea, etc., that is, the adverse reactions caused by the administration of orlistat cannot be effectively solved.
Chinese patent CN101420951a discloses a pharmaceutical composition comprising a lipase inhibitor and a lipophilic oil absorbent and an oral formulation prepared therefrom. Wherein the lipophilic oil absorbent is capable of adsorbing non-absorbed oils and fats, and minimizing side effects of the lipase inhibitor. However, the finished product prepared by the invention has complex formula components, higher cost and no auxiliary effect on losing weight of orlistat, and experiments prove that the effect on improving the oil stain is inferior to that of the invention.
Chinese patent CN1649580a contains a pharmaceutical composition of lipase inhibitor and glucomannan for treating and preventing obesity, and alleviating adverse effects of oil spot, fat feces, etc. caused by orlistat. However, glucomannan in the composition has no effect of assisting orlistat in enhancing weight loss effect, and also has no effect of regulating intestinal functions. Moreover, in the invention, the drug combination is taken, and the free oil of 5 volunteers is reduced by at least 50% to indicate effective effect, so that the number of subjects is small, the evaluation standard is low, and the persuasion is insufficient.
The invention comprises the following steps:
a first aspect of the present invention aims to overcome the deficiencies of the prior art and to provide a composition of probiotics and prebiotics for use with orlistat.
A second aspect of the present invention aims to provide the use of a composition of probiotics and prebiotics in a food product assisting the action of orlistat in enhancing the efficacy of weight loss. In order to achieve the above object of the present invention, the following technical scheme is adopted:
a composition of probiotics and prebiotics comprising resistant dextrin, inulin, corn starch, stachyose and lactic acid bacteria.
Further, the probiotics comprise lactobacillus plantarum, lactobacillus acidophilus, bifidobacterium bifidum and lactobacillus paracasei.
Further, the bifidobacterium bifidum is selected from bifidobacterium bifidum TMC3115.
Further, the composition also comprises auxiliary materials.
Further, the auxiliary materials comprise a filling agent and a flavoring agent (including a sweetener), the addition amount of the auxiliary materials is the addition amount conventional in the field, and the addition of the auxiliary materials should meet the national standards for food additives or be pharmaceutically acceptable auxiliary materials.
Further, in order to obtain a better functional effect, the brewing temperature is not higher than 37 ℃; the composition is administered half an hour after meals; if antibiotics are used, the antibiotics can be eaten after two hours; the inulin consumption is less than or equal to 15 g/day.
Further, the composition of probiotics and prebiotics comprises the following components in parts by weight:
further, the composition of probiotics and prebiotics comprises the following components in parts by weight:
the combination of the probiotics and the prebiotics or the combination of the probiotics comprises the following steps: weighing the prescription amount of resistant dextrin, inulin, corn starch, stachyose and auxiliary materials, mixing and stirring, sterilizing, adding lactobacillus plantarum, lactobacillus acidophilus, bifidobacterium bifidum and lactobacillus paracasei, uniformly mixing, and finally preparing the finished product.
The composition of probiotics and prebiotics can be made into pill, tablet, capsule, powder, granule, and oral liquid.
Compared with the traditional method, the technical scheme of the invention has the following steps:
synergistic effect, and enhanced weight loss effect. The orlistat can inhibit fat absorption, and the composition and the orlistat are matched for administration to have complementary effects, so that the weight-losing curative effect is more remarkable.
The specific embodiment is as follows:
the following is a further detailed description of the invention in connection with certain preferred embodiments, and it is not to be construed that the invention is limited to such embodiments. It should be understood that, for those skilled in the art, several simple deductions or substitutions may be made without departing from the spirit of the present invention, and all technical and index parts used in the present invention but not described in the present invention are all prior art.
Unless otherwise specifically indicated, the various raw materials, reagents, instruments, equipment and the like used in the present invention are commercially available or may be prepared by existing methods.
Example 1
A composition of probiotics and prebiotics comprising the following components in parts by weight:
the preparation process comprises the following steps:
weighing the prescription amount of resistant dextrin, inulin, corn starch, stachyose, maltodextrin and sweetener, mixing, stirring, sterilizing, adding lactobacillus plantarum, lactobacillus acidophilus, bifidobacterium bifidum and lactobacillus paracasei, mixing uniformly, granulating by wet method, drying, granulating, and packaging to obtain the granule.
Example 2
A composition of probiotics and prebiotics comprising the following components in parts by weight:
the preparation process comprises the following steps:
weighing the prescription amount of resistant dextrin, inulin, corn starch, stachyose, maltodextrin and sweetener, mixing, stirring, sterilizing, adding lactobacillus plantarum, lactobacillus acidophilus, bifidobacterium bifidum and lactobacillus paracasei, mixing uniformly, granulating, and encapsulating to obtain the capsule.
Example 3
A composition of probiotics and prebiotics comprising the following components in parts by weight:
the preparation process comprises the following steps:
weighing the prescription amount of resistant dextrin, inulin, corn starch, stachyose, maltodextrin and sweetener, mixing, stirring, sterilizing, adding lactobacillus plantarum, lactobacillus acidophilus, bifidobacterium bifidum and lactobacillus paracasei, mixing, granulating, tabletting, and coating with film to obtain tablet.
Example 4
A composition of probiotics and prebiotics comprising the following components in parts by weight:
the preparation process comprises the following steps:
weighing the prescription amount of resistant dextrin, inulin, corn starch, stachyose, maltodextrin and sweetener, mixing, stirring, sterilizing, adding lactobacillus plantarum, lactobacillus acidophilus, bifidobacterium bifidum and lactobacillus paracasei, mixing, sieving with 80 mesh sieve to obtain fine powder, and packaging to obtain powder.
Example 5
A composition of probiotics and prebiotics comprising the following components in parts by weight:
the preparation process comprises the following steps:
weighing the prescription amount of resistant dextrin, inulin, corn starch, stachyose, maltodextrin and sweetener, mixing, stirring, sterilizing, adding lactobacillus plantarum, lactobacillus acidophilus, bifidobacterium bifidum and lactobacillus paracasei, mixing, adding water, stirring, making pill on an automatic pill making machine, polishing, vacuum drying, and packaging to obtain pill.
Example 6
A composition of probiotics and prebiotics comprising the following components in parts by weight:
the preparation process comprises the following steps:
weighing the prescription amount of resistant dextrin, inulin, corn starch, stachyose, maltodextrin and sweetener, mixing, stirring, sterilizing, adding lactobacillus plantarum, lactobacillus acidophilus, bifidobacterium bifidum and lactobacillus paracasei, mixing, adding water, stirring, and canning to obtain the oral liquid.
Comparative example 1
A composition of probiotics and prebiotics comprising the following components in parts by weight:
the preparation process comprises the following steps:
weighing the prescription amount of resistant dextrin, inulin, corn starch, stachyose, maltodextrin and sweetener, mixing, stirring, sterilizing, adding lactobacillus plantarum, lactobacillus acidophilus and lactobacillus paracasei, mixing uniformly, granulating by wet method, drying, finishing, and packaging to obtain the granule.
Comparative example 2
A composition of probiotics and prebiotics comprising the following components in parts by weight:
the preparation process comprises the following steps:
weighing the prescription amount of resistant dextrin, inulin, corn starch, stachyose, maltodextrin and sweetener, mixing, stirring, sterilizing, adding bifidobacterium bifidum and lactobacillus paracasei, mixing, adding water, stirring, and canning to obtain the oral liquid.
Comparative example 3
A composition of probiotics and prebiotics comprising the following components in parts by weight:
the preparation process comprises the following steps:
weighing the prescription amount of resistant dextrin, inulin, corn starch, stachyose, maltodextrin and sweetener, mixing, stirring, sterilizing, mixing, granulating by wet method, drying, grading, and packaging to obtain granule.
Comparative example 4
A composition of probiotics and prebiotics comprising the following components in parts by weight:
the preparation process comprises the following steps:
weighing the prescription amount of resistant dextrin, corn starch, stachyose, maltodextrin and sweetener, mixing, stirring, sterilizing, adding lactobacillus plantarum, lactobacillus acidophilus, bifidobacterium bifidum and lactobacillus paracasei, mixing, sieving with 80 mesh sieve to obtain fine powder, and packaging to obtain powder.
Comparative example 5
A composition of probiotics and prebiotics comprising the following components in parts by weight:
the preparation process comprises the following steps:
weighing inulin, corn starch, maltodextrin and sweetener, mixing, sterilizing, adding lactobacillus plantarum, lactobacillus acidophilus, bifidobacterium bifidum and lactobacillus paracasei, mixing, granulating, tabletting, and coating.
Comparative example 6
A composition of probiotics and prebiotics comprising the following components in parts by weight:
the preparation process comprises the following steps:
weighing maltodextrin and sweetener, mixing, sterilizing, adding lactobacillus plantarum, lactobacillus acidophilus, bifidobacterium bifidum and lactobacillus paracasei, mixing, granulating, and making into hard capsule.
Experimental example 1
The composition of probiotics and prebiotics assists the weight-losing efficacy drug of orlistat on mice: suljia brand orlistat capsule, 21 pieces of which each contains 0.12g of orlistat, manufacturer: shandong New age pharmaceutical Co., ltd.
1 preparation of animal model
The KM mice of 4 weeks old, male and female, provided by Lunan pharmaceutical laboratory animal center, were fed with high-fat feed (the formulation of the high-fat feed is 1kg casein, 15g L-cysteine, 0.75kg maltodextrin, 0.35kg sucrose, 0.25kg cellulose, 0.15kg soybean oil, and 1.25kg lard). After 10 weeks of feeding, mice weighing less than 60g were eliminated and then dosed in groups.
2 grouping and administration
Rats successfully molded were randomly divided into the following groups according to body weight:
model group: physiological saline of the same volume
Orlistat group: 40 mg/(kg.d) orlistat
Orlistat + example 1 composition group of probiotics and prebiotics: 40 mg/(kg.d) orlistat+1500 mg/(kg.d)
Orlistat + example 2 composition group of probiotics and prebiotics: 40 mg/(kg.d) orlistat+1500 mg/(kg.d)
Orlistat + example 3 composition group of probiotics and prebiotics: 40 mg/(kg.d) orlistat+1500 mg/(kg.d)
Orlistat + example 4 composition group of probiotics and prebiotics: 40 mg/(kg.d) orlistat+1500 mg/(kg.d)
Orlistat + example 5 composition group of probiotics and prebiotics: 40 mg/(kg.d) orlistat+1500 mg/(kg.d)
Orlistat + example 6 composition group of probiotics and prebiotics: 40 mg/(kg.d) orlistat+1500 mg/(kg.d)
Orlistat + comparative example 1 composition group of probiotics and prebiotics: 40 mg/(kg.d) orlistat+1500 mg/(kg.d)
Orlistat + comparative example 2 composition group of probiotics and prebiotics: 40 mg/(kg.d) orlistat+1500 mg/(kg.d)
Orlistat + comparative example 3 composition group of probiotics and prebiotics: 40 mg/(kg.d) orlistat+1500 mg/(kg.d)
Orlistat + comparative example 4 composition group of probiotics and prebiotics: 40 mg/(kg.d) orlistat+1500 mg/(kg.d)
Orlistat + comparative example 5 composition group of probiotics and prebiotics: 40 mg/(kg.d) orlistat+1500 mg/(kg.d)
Orlistat + comparative example 6 composition group of probiotics and prebiotics: 40 mg/(kg.d) orlistat+1500 mg/(kg.d)
Each group was fed with high fat diet during the dosing period, three times per day, at 6:00, 14:00, 22: the stomach was irrigated for 8 consecutive weeks at 00.
3 weight measurement
The body weight was weighed every 2 weeks from the 2 nd week after the administration, and the experimental results are shown in Table 1.
Table 1 influence of groups on body weight of mice (unit: g)
* P <0.05 compared to model group; * Comparing P <0.01 to the model group;
# compared to orlistat group, P <0.05; # compared to orlistat group, P <0.01.
4 experimental results: week 4, all other groups were significantly different from the model group; from week 6, all other groups were very significantly different from the model group. At week 6, only the orlistat + example 1 group, the orlistat + example 2 group and the orlistat + example 6 group were significantly different from the orlistat group. At week 8, orlistat + example 1 showed very significant differences compared to the orlistat group. The result shows that the orlistat and the probiotic and prebiotic composition with optimized proportion have good synergistic effect when being applied to weight reduction, and a proper amount of bifidobacterium bifidum TMC3115 is added to the probiotic and prebiotic composition to have good synergistic weight reduction effect when being combined with the orlistat. The combined application of the orlistat and the prebiotic composition or the orlistat and the probiotic composition is not different from that of the orlistat only in weight losing effect, and has no obvious difference.
The combined use of orlistat and glucomannan in example 2 of chinese patent CN1649580a did not significantly differ from the weight loss effect of orlistat alone, and the patent text also showed no interaction between glucomannan and orlistat, i.e. the glucomannan and orlistat in the patent did not act synergistically, and could not be used to assist in weight loss.
Claims (4)
1. Use of a composition of probiotics and prebiotics for the preparation of a food product for aiding in enhancing the slimming efficacy of orlistat, characterized in that said composition comprises:
30 parts of resistant dextrin, 15 parts of inulin, 8 parts of corn starch, 15 parts of maltodextrin, 12 parts of stachyose, 5 parts of lactobacillus plantarum, 6 parts of lactobacillus acidophilus, 8 parts of bifidobacterium bifidum, 5 parts of lactobacillus paracasei and 1 part of sweetener;
or 25 parts of resistant dextrin, 11 parts of inulin, 6 parts of corn starch, 12 parts of maltodextrin, 9 parts of stachyose, 8 parts of lactobacillus plantarum, 7 parts of lactobacillus acidophilus, 9 parts of bifidobacterium bifidum, 5 parts of lactobacillus paracasei and 5 parts of sweetener;
or 28 parts of resistant dextrin, 15 parts of inulin, 7 parts of corn starch, 15 parts of maltodextrin, 14 parts of stachyose, 5 parts of lactobacillus plantarum, 5 parts of lactobacillus acidophilus, 7 parts of bifidobacterium bifidum, 4 parts of lactobacillus paracasei and 2 parts of sweetener.
2. Use of a composition of probiotics and prebiotics according to claim 1 for the preparation of a food product to assist in enhancing the weight loss efficacy of orlistat, characterized in that the bifidobacterium bifidum is bifidobacterium bifidum TMC3115.
3. Use of a composition of probiotics and prebiotics according to claim 1 for the preparation of a food product to assist in enhancing the slimming efficacy of orlistat, characterized in that the composition is selected from the following forms: pill, tablet, capsule, powder, granule or oral liquid.
4. A process for the preparation of a composition of probiotics and prebiotics as claimed in any one of claims 1 to 3, comprising the steps of: weighing the prescription amount of resistant dextrin, inulin, corn starch, stachyose, maltodextrin and sweetener, mixing, sterilizing, adding lactobacillus plantarum, lactobacillus acidophilus, bifidobacterium bifidum and lactobacillus paracasei, mixing uniformly, and finally preparing into a finished product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211459787.9A CN115671132B (en) | 2020-06-01 | 2021-05-31 | Composition of probiotics and prebiotics and application thereof |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020104861471 | 2020-06-01 | ||
| CN202010486147 | 2020-06-01 | ||
| CN202211459787.9A CN115671132B (en) | 2020-06-01 | 2021-05-31 | Composition of probiotics and prebiotics and application thereof |
| CN202110599523.2A CN113750113B (en) | 2020-06-01 | 2021-05-31 | Composition of probiotics and prebiotics and application thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110599523.2A Division CN113750113B (en) | 2020-06-01 | 2021-05-31 | Composition of probiotics and prebiotics and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115671132A CN115671132A (en) | 2023-02-03 |
| CN115671132B true CN115671132B (en) | 2024-03-15 |
Family
ID=78787331
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110599523.2A Active CN113750113B (en) | 2020-06-01 | 2021-05-31 | Composition of probiotics and prebiotics and application thereof |
| CN202211459787.9A Active CN115671132B (en) | 2020-06-01 | 2021-05-31 | Composition of probiotics and prebiotics and application thereof |
| CN202211439642.2A Pending CN115737672A (en) | 2020-06-01 | 2021-05-31 | Composition of probiotics and prebiotics and application thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110599523.2A Active CN113750113B (en) | 2020-06-01 | 2021-05-31 | Composition of probiotics and prebiotics and application thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211439642.2A Pending CN115737672A (en) | 2020-06-01 | 2021-05-31 | Composition of probiotics and prebiotics and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (3) | CN113750113B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114376235B (en) * | 2022-01-26 | 2024-04-09 | 广州美春堂医药科技有限公司 | Weight-losing probiotics and prebiotic composition for controlling body fat and preparation method thereof |
| CN115154516B (en) * | 2022-08-22 | 2023-09-01 | 合生元（广州）健康产品有限公司 | Composition for improving appetite and/or promoting digestion and absorption and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1649580A (en) * | 2002-04-26 | 2005-08-03 | 霍夫曼-拉罗奇有限公司 | Pharmaceutical composition comprising a lipase inhibitor and glucomannan |
| CN110024932A (en) * | 2019-04-29 | 2019-07-19 | 哈尔滨求真生物科技有限公司 | A kind of black fungus extract solid drink formula and preparation method thereof for losing weight, improving diarrhea, adjust flora |
| CN110150669A (en) * | 2019-04-29 | 2019-08-23 | 河北一然生物科技有限公司 | A kind of probiotic composition and its application suitable for patients with diabetes mellitus |
| WO2021073197A1 (en) * | 2019-10-14 | 2021-04-22 | 鲁南制药集团股份有限公司 | Composition containing lactic acid bacteria and use thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10324548A1 (en) * | 2003-05-28 | 2004-12-16 | Nutrinova Nutrition Specialties & Food Ingredients Gmbh | Dietary food with a weight-controlling or weight-reducing diet |
| CN101608172B (en) * | 2009-07-24 | 2013-01-23 | 南京华贞生物医药科技有限公司 | Transformant for reducing weight and fat and preparation method thereof |
| CN104955467A (en) * | 2012-11-12 | 2015-09-30 | 热尔韦·达诺尼公司 | Lactobacillus rhamnosus strain for reducing body fat accumulation |
| CN106072547A (en) * | 2016-06-28 | 2016-11-09 | 张标 | A kind of probiotic powder with fat-reducing and regulation gastrointestinal function |
| WO2018045493A1 (en) * | 2016-09-06 | 2018-03-15 | 深圳华大基因研究院 | Christensenella intestinihominis and application thereof |
| CN107125767B (en) * | 2017-04-28 | 2020-09-29 | 黑龙江大学 | Preparation method and application of bifidobacterium breve, lactobacillus fermentum and lactobacillus plantarum three-bacterium composite micro-particles |
| CN109223833A (en) * | 2017-07-10 | 2019-01-18 | 上海立龙生物科技有限公司 | A kind of probiotic composition of prevention and improvement obesity |
| CN109170909A (en) * | 2018-10-10 | 2019-01-11 | 河北畅然生物科技有限公司 | A kind of compound probiotic and prebiotic compositions and preparation method thereof improving constipation |
| CN109619595A (en) * | 2018-12-27 | 2019-04-16 | 天津活力达生物科技有限公司 | A kind of composition and its application containing profitable probliotics and prebiotics |
| CN110051003A (en) * | 2019-04-24 | 2019-07-26 | 广州能靓生物技术有限公司 | A kind of compound probiotic composition and its application |
| CN110151796B (en) * | 2019-05-09 | 2020-02-04 | 中科宜康（北京）生物科技有限公司 | Probiotics and prebiotics composition capable of forming lean body mass and application thereof |
| CN110447902B (en) * | 2019-09-10 | 2024-02-20 | 广州宏韵医药科技股份有限公司 | Composition with weight-losing effect |
| CN110559384A (en) * | 2019-09-11 | 2019-12-13 | 君维安(武汉)生命科技有限公司 | Traditional Chinese medicine prebiotic composition and preparation method and application thereof |
| CN110464808A (en) * | 2019-09-11 | 2019-11-19 | 君维安(武汉)生命科技有限公司 | Weight-reducing and lipid-lowering Chinese medicine prebiotic compositions and its preparation method and application |
| CN111096416A (en) * | 2019-12-26 | 2020-05-05 | 宁波御坊堂生物科技有限公司 | Diet-depriving composition for weight-losing meal replacement and preparation method thereof |
| CN111053190A (en) * | 2019-12-26 | 2020-04-24 | 宁波御坊堂生物科技有限公司 | Light-weight food composition for weight-losing meal replacement and preparation method thereof |
-
2021
- 2021-05-31 CN CN202110599523.2A patent/CN113750113B/en active Active
- 2021-05-31 CN CN202211459787.9A patent/CN115671132B/en active Active
- 2021-05-31 CN CN202211439642.2A patent/CN115737672A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1649580A (en) * | 2002-04-26 | 2005-08-03 | 霍夫曼-拉罗奇有限公司 | Pharmaceutical composition comprising a lipase inhibitor and glucomannan |
| CN110024932A (en) * | 2019-04-29 | 2019-07-19 | 哈尔滨求真生物科技有限公司 | A kind of black fungus extract solid drink formula and preparation method thereof for losing weight, improving diarrhea, adjust flora |
| CN110150669A (en) * | 2019-04-29 | 2019-08-23 | 河北一然生物科技有限公司 | A kind of probiotic composition and its application suitable for patients with diabetes mellitus |
| WO2021073197A1 (en) * | 2019-10-14 | 2021-04-22 | 鲁南制药集团股份有限公司 | Composition containing lactic acid bacteria and use thereof |
Non-Patent Citations (5)
| Title |
|---|
| 新型减肥药奥利司他的研究进展;马微等;《华西药学杂志》;第24卷(第4期);第431-433页 * |
| 益生菌剂调整肠道疾病人群菌群结构丰度水平的研究;臧凯丽等;《食品科学》;第39卷(第13期);第133-143页 * |
| 益生菌胞外蛋白与肠道粘膜免疫细胞互作关系的研究进展;臧凯丽等;《食品工业科技》;第39卷(第14期);第346-351页 * |
| 臧凯丽等.益生菌剂调整肠道疾病人群菌群结构丰度水平的研究.《食品科学》.2018,第39卷(第13期),第133-143页. * |
| 臧凯丽等.益生菌胞外蛋白与肠道粘膜免疫细胞互作关系的研究进展.《食品工业科技》.2018,第39卷(第14期),第346-351页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115671132A (en) | 2023-02-03 |
| CN113750113B (en) | 2022-12-02 |
| CN115737672A (en) | 2023-03-07 |
| CN113750113A (en) | 2021-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101911205B1 (en) | Composition for defecation inducement and diet and producing method thereof | |
| CN115074274B (en) | Lactic acid bacteria-containing composition and use thereof | |
| CN115671132B (en) | Composition of probiotics and prebiotics and application thereof | |
| CN100512667C (en) | Pig feed addictive | |
| WO2018181380A1 (en) | Edible composition for intestinal bacteria | |
| CN105249480A (en) | Chewable tablet with dietary fiber and bifidobacteria and preparing method thereof | |
| JP2816726B2 (en) | Composition for improving intestinal environment | |
| CN105029393A (en) | Medical formula food for children | |
| JP6945888B1 (en) | Composition for improving immune function | |
| Tabrizi et al. | Functional laxative foods: Concepts, trends and health benefits | |
| CN105029392A (en) | Medical formula food for nasopharynx cancer | |
| CN108523123A (en) | A kind of full nutritional support food of diabetes | |
| CN104146312B (en) | The health products of regulating gastointestinal function | |
| JPH09154535A (en) | Natto (fermented soybean)-containing composition | |
| KR20220058176A (en) | Prebiotics composition for improving intestinal microflora | |
| TWI815258B (en) | Prebiotic composition and cajanus composition use for adjusting human gut microbiota | |
| JP2003339350A (en) | Diet food | |
| US8993639B2 (en) | Compound and method for treatment of gastroesophageal reflux | |
| JP7257665B2 (en) | oral composition | |
| JP7280649B1 (en) | oral composition | |
| KR102609638B1 (en) | Composition comprising underia pinnatifida sporophyll hot-water extract for improving gut microbiome | |
| WO2020179810A1 (en) | Composition for increasing occupancy of faecalibacterium in intestinal flora | |
| CN113456704B (en) | Pharmaceutical composition with gastrointestinal improving effect and preparation method and application thereof | |
| JP2003052334A (en) | Diet food | |
| JP2023037531A (en) | Food, food set, dried powder and oral composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |